Results 31 to 40 of about 13,526 (188)

Nintedanib ameliorates experimental pulmonary arterial hypertension via inhibition of endothelial mesenchymal transition and smooth muscle cell proliferation.

PLoS ONE, 2019
Neointimal lesion and medial wall thickness of pulmonary arteries (PAs) are common pathological findings in pulmonary arterial hypertension (PAH). Platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) signaling contribute to intimal ...
Takeo Tsutsumi, Tetsutaro Nagaoka, Takashi Yoshida, Lei Wang, Sachiko Kuriyama, Yoshifumi Suzuki, Yuichi Nagata, Norihiro Harada, Yuzo Kodama, Fumiyuki Takahashi, Yoshiteru Morio, Kazuhisa Takahashi   +11 more
doaj   +1 more source

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis

BMC Pulmonary Medicine, 2020
Background The two 52-week INPULSIS trials investigated nintedanib versus placebo in patients with IPF, FVC ≥50% predicted and DLco 30–79% predicted. The 24-week INSTAGE trial investigated nintedanib plus sildenafil versus nintedanib alone in patients ...
Luca Richeldi, Martin Kolb, Stéphane Jouneau, Wim A. Wuyts, Birgit Schinzel, Susanne Stowasser, Manuel Quaresma, Ganesh Raghu   +7 more
doaj   +1 more source

Nintedanib-Induced Renal Thrombotic Microangiopathy

Case Reports in Nephrology and Dialysis, 2021
Nintedanib is a unique tyrosine kinase inhibitor used to suppress fibrosis in patients with idiopathic pulmonary fibrosis (IPF). Nintedanib has been shown to suppress multiple processes of fibrosis, thereby reducing the rate of lung function decline in ...
Takeshi Fujita, Hideyuki Nakagawa, Takashi Yokota, Jun Umetani, Daiki Nagawa, Masamichi Nakata, Ikuyo Narita-Kinjo, Reiichi Murakami, Michiko Shimada, Norio Nakamura, Hirofumi Tomita   +10 more
doaj   +1 more source

Nintedanib, Pirfenidone and the combination

, 2022
Pairwise meta-analysis on nintedanib, pirfenidone and the combination of the ...
Tyler Pitre
core   +1 more source

Effect of nintedanib on acute exacerbations of fibrosing interstitial lung diseases: a national database study in Japan

ERJ Open Research, 2022
Background Acute exacerbation is a life-threatening event in patients with fibrosing interstitial lung diseases (ILDs). Although nintedanib reduces acute exacerbation incidence, its effectiveness during acute exacerbation is unclear.
Hirokazu Urushiyama, Taisuke Jo, Wakae Hasegawa, Akira Yokoyama, Takahiro Ando, Yukiyo Sakamoto, Ryosuke Kumazawa, Kazuaki Uda, Nobuaki Michihata, Nobuyasu Awano, Matsui Hiroki, Kiyohide Fushimi, Hideo Yasunaga, Takahide Nagase   +13 more
doaj   +1 more source

Association of Elevated Platelets and C‐Reactive Protein With Severe Disease and Poor Survival in Systemic Sclerosis

Arthritis Care &Research, EarlyView.
Objective Elevated C‐reactive protein (CRP) levels in systemic sclerosis (SSc) have been linked with severe disease and worse survival, but the role of platelet levels remains unclear. This study examined whether elevated platelet levels, CRP levels, or both are associated with disease severity, progression, and survival in SSc.
Brian S. Lee, Shufeng Li, Srijana Davuluri, Jennifer Lee, Lorinda Chung   +4 more
wiley   +1 more source

Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer

Journal of Experimental & Clinical Cancer Research, 2017
Background Studying the intracellular distribution of pharmacological agents, including anticancer compounds, is of central importance in biomedical research. It constitutes a prerequisite for a better understanding of the molecular mechanisms underlying
Bernhard Englinger, Sebastian Kallus, Julia Senkiv, Daniela Heilos, Lisa Gabler, Sushilla van Schoonhoven, Alessio Terenzi, Patrick Moser, Christine Pirker, Gerald Timelthaler, Walter Jäger, Christian R. Kowol, Petra Heffeter, Michael Grusch, Walter Berger   +14 more
doaj   +1 more source

Tolerability of nintedanib in the elderly with idiopathic pulmonary fibrosis: A single-center retrospective study.

PLoS ONE, 2022
Idiopathic pulmonary fibrosis (IPF), a fibrosing interstitial lung disease, predominantly affects the elderly and is associated with a high mortality risk. Nintedanib, a tyrosine kinase inhibitor, significantly reduces IPF progression.
Masamichi Komatsu, Hiroshi Yamamoto, Takashi Ichiyama, Satoshi Kawakami, Takeshi Uehara, Yumi Yoshikawa, Yoshiaki Kitaguchi, Atsuhito Ushiki, Masanori Yasuo, Masayuki Hanaoka   +9 more
doaj   +1 more source

Human microvasculature-on-a chip: anti-neovasculogenic effect of nintedanib in vitro [PDF]

, 2018
Idiopathic pulmonary fibrosis is characterized by a progressive scarring and stiffening of the peripheral lung tissue that decreases lung function. Over the course of the disease, the lung microvasculature undergoes extensive remodeling.
Hobi, Nina, Schmid, Ralph A., Bichsel, Colette A., Zeinali, Soheila, Marti, Thomas M., Guenat, Olivier T., Funke, Manuela, Geiser, Thomas   +7 more
core   +2 more sources

Engineered Nanoplatforms Targeting Activated Hepatic Stellate Cells for Liver Fibrosis Therapy via TGF‐β Axis Inhibition and Ferroptosis Induction

Advanced Healthcare Materials, EarlyView.
FeS‐VA@lanifibranor (FVL), an activated hepatic stellate cell (aHSC)‐targeted nanoplatform comprising vitamin A‐functionalized two‐dimensional iron sulfide nanosheets and lanifibranor, is engineered for precision therapy of liver fibrosis. FVL suppresses the TGF‐β signaling pathway by inhibiting SMAD2/3 phosphorylation and induces ferroptosis in aHSCs,
Yinuo Yang, Mengyao Mu, Ke Ren, Hui Liu, Pengju Ma, Yingqi Wang, Mengmeng Zhang, Xueli Xu, Wenzhe Li, Wenshuang Gao, Xiao Sun, Qiang Zhu   +11 more
wiley   +1 more source